Italia markets closed
Dow Jones
32.774,41 +56,81 (+0,17%) Nasdaq
12.014,60 +88,37 (+0,74%) Nikkei 225
27.782,93 -100,85 (-0,36%) EUR/USD
1,0900 +0,0053 (+0,49%) Bitcoin EUR
26.008,75 -87,90 (-0,34%) CMC Crypto 200
616,85 -2,39 (-0,39%)
Exelixis, Inc. (0IJO.L)
LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 04:18PM BST
| Chiusura precedente | 18,57 |
| Aperto | 19,01 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 19,01 - 19,01 |
| Intervallo di 52 settimane | 19,01 - 19,01 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 58,689M |
| Beta (5 anni mensile) | 0,69 |
| Rapporto PE (ttm) | 0,21 |
| EPS (ttm) | 0,92 |
| Prossima data utili | 02 mag 2023 - 08 mag 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe, who most recently served as President and Chief Financial Officer of Myovant Sciences, Inc. (NYSE:MYOV), brings over twenty-five years of financial and life-sciences expertise to Phathom. “We are
© 2023 Yahoo. Tutti i diritti riservati.
